FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference
This article was originally published in The Pink Sheet Daily
Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.
You may also be interested in...
FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.